InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,562.12
(
-0.47%
)
US TECH 100
19,182.40
(
-0.46%
)
Dow Jones
40,926.23
(
-0.66%
)
Brent Oil
84.48
(
-0.01%
)
Bitcoin
63,802.43
(
-0.44%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 84
Posts 12487
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Tuesday, 12/09/2014 9:47:35 AM

Tuesday, December 09, 2014 9:47:35 AM

Post# of 80490

22% of CP-CML patients experienced an arterial thrombotic serious adverse event (SAE), and 27 percent of CP-CML patients experienced any arterial thrombotic event

This means Ponatinib is finished.

Iclusig arterial thrombotic SAE rate continues to rise even after significant dose reduction. Compare the above numbers from 38-month follow-up against ASCO2014 30-month follow-up of 16% arterial thrombotic SAE, and 23% any arterial thrombotic event.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up